Immutep Completes Patient Enrolment In Randomised Phase II Of AIPAC-003 Trial In Metastatic Breast Cancer
Portfolio Pulse from Benzinga Newsdesk
Immutep Limited has completed patient enrollment for the Phase II AIPAC-003 trial, testing eftilagimod alpha with paclitaxel in metastatic breast cancer patients. The trial aims to determine the optimal biological dose, aligning with FDA's Project Optimus.
October 03, 2024 | 12:04 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Immutep has completed enrollment for its Phase II AIPAC-003 trial, which could impact its stock positively if results show efficacy in treating metastatic breast cancer.
The completion of patient enrollment in a clinical trial is a significant milestone for biotech companies. If the trial results are positive, it could lead to increased investor confidence and a potential rise in stock price. The trial's alignment with FDA's Project Optimus further underscores its importance.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90